Abstract
The cellular genome is constantly subject to DNA damage caused by endogenous factors or exogenously by damaging agents such as ionizing radiation or various anticancer agents. The base excision repair (BER) enzyme, DNA polymerase β, and the polymerases involved in translesion synthesis (TLS) have been shown to contribute to cellular tolerance and repair of DNA lesions by anticancer treatments, particularly the platinum cytotoxic drugs. Moreover, there is robust preclinical evidence linking alterations in DNA pol β and TLS polymerase levels to cancer. DNA polymerases may therefore be potential targets to increase the sensitivity of cancer cells to chemotherapy drugs. In this article, the physical and chemical properties of DNA polymerase β and the translesion synthesis polymerases are reviewed with a view to identifying how they may act as targets for anticancer treatment. The potential clinical role of new DNA polymerase inhibitors is discussed and how they may be combined with conventional cytotoxic agents.
Keywords: Base excision repair, cisplatin, DNA damage repair, DNA polymerase, oxaliplatin, radiotherapy, translesion synthesis
Current Molecular Pharmacology
Title: Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Volume: 5
Author(s): Nils H. Nicolay, Thomas Helleday and Ricky A. Sharma
Affiliation:
Keywords: Base excision repair, cisplatin, DNA damage repair, DNA polymerase, oxaliplatin, radiotherapy, translesion synthesis
Abstract: The cellular genome is constantly subject to DNA damage caused by endogenous factors or exogenously by damaging agents such as ionizing radiation or various anticancer agents. The base excision repair (BER) enzyme, DNA polymerase β, and the polymerases involved in translesion synthesis (TLS) have been shown to contribute to cellular tolerance and repair of DNA lesions by anticancer treatments, particularly the platinum cytotoxic drugs. Moreover, there is robust preclinical evidence linking alterations in DNA pol β and TLS polymerase levels to cancer. DNA polymerases may therefore be potential targets to increase the sensitivity of cancer cells to chemotherapy drugs. In this article, the physical and chemical properties of DNA polymerase β and the translesion synthesis polymerases are reviewed with a view to identifying how they may act as targets for anticancer treatment. The potential clinical role of new DNA polymerase inhibitors is discussed and how they may be combined with conventional cytotoxic agents.
Export Options
About this article
Cite this article as:
H. Nicolay Nils, Helleday Thomas and A. Sharma Ricky, Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment, Current Molecular Pharmacology 2012; 5 (1) . https://dx.doi.org/10.2174/1874467211205010054
DOI https://dx.doi.org/10.2174/1874467211205010054 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Regulation of Tumor Immune Microenvironment by Sphingolipids and Lysophosphatidic Acid
Current Drug Targets Single Chemical Entity Legal Highs: Assessing the Risk for Long Term Harm
Current Drug Abuse Reviews Human Carcinogenesis and Bracken Fern: A Review of the Evidence
Current Medicinal Chemistry Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Azo Dye Degrading Enzyme Research
Current Protein & Peptide Science Effects of Dietary Broccoli on Human in Vivo Caffeine Metabolism: A Pilot Study on a Group of Jordanian Volunteers
Current Drug Metabolism Proteomics as a Tool in the Pharmaceutical Drug Design Process
Current Pharmaceutical Design Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Protein & Peptide Letters Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery